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Abstract 
Background: Cardiac syndrome X (CSX) is characterized by angina pectoris but with patent coronary arteries. Our 
previous study demonstrated that subjects with CSX had a higher fasting insulin‑resistance (IR) than the controls. 
However, few studies have investigated the degree of IR, including oral glucose tolerance test (OGTT)‑derived indices 
and profiles of metabolic abnormalities between CSX and coronary artery disease (CAD).
Methods: Ninety‑two CSX and 145 CAD subjects without known diabetes mellitus (DM) underwent coronary angio‑
gram (CAG) for angina pectoris and also agreed to receive OGTT and glycated hemoglobin (HbA1C) evaluations for 
screening abnormal glucose regulation and IR.
Results: CAD group had more subjects with metabolically unhealthy obesity (52.4 vs. 31.5%, p < 0.001) than the CSX 
group. The CAD group had higher OGTT 2 h glucose and insulin (both p < 0.005) while fasting glucose, insulin and 
HOMA‑IR were similar to those of CSX subjects. In the binary regression analysis, OGTT 2 h insulin and being meta‑
bolic unhealthy were significantly different between the CAD and CSX groups, but there were no significant differ‑
ences in Matsuda index, fasting glucose, insulin, HOMA‑IR, or HbA1C.
Conclusions: Post challenge OGTT 2 h insulin and being metabolic unhealthy were useful parameters in differentiat‑
ing between CAD and CSX in subjects without known DM but suffered from angina pectoris and underwent CAG. 
Different degrees of IR and metabolic abnormalities might be implicated in the pathogenesis of micro vs. macro 
vascular coronary diseases.
Trial registration NCT01198730 at https://clinicaltrials.gov, Registered Sep. 8, 2010
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Background
Subjects with cardiac syndrome X (CSX) have angina-
like symptoms with evidence of ischemia on stress elec-
trocardiogram or isotope perfusion scan but with patent 
epicardial coronary arteries on coronary angiogram 
(CAG) [1–3]. The proposed mechanisms underlying CSX 
include endothelial dysfunction with impaired vaso-dila-
tory reserve in micro-vascular beds, inflammation, insu-
lin resistance (IR), estrogen deficiency, or oxidative stress 
[4–6].
Studies have reported hyper-insulinemia during oral or 
intravenous glucose tolerance test was more prominent 
in the CSX group than in controls, which implies that IR 
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hyper-insulinemia and the euglycemia clamp test, other 
investigators found that subjects with CSX had a higher 
degree of IR as compared to controls [9, 10]. In addition, 
CSX subjects more commonly had metabolic syndrome 
and related adiposity, metabolic, and inflammatory 
derangements [3, 11]. Our previous studies showed that 
CSX subjects had a higher IR, had more with hyperten-
sion, and a non-significantly higher body mass index 
(BMI) compared with the control group [6, 12]. Meta-
bolic abnormalities and obesity increase the risk of future 
coronary artery disease (CAD) [13, 14]. Studies on non-
diabetic participants showed that subjects with angio-
graphically documented CAD exhibited moderate-severe 
IR and hyperinsulinemia [15, 16]. A study by Chauhan 
et al. [17] reported that there was a greater rise in insu-
lin levels in response to a glucose challenge in those with 
CSX than in controls, and further showed that this rise 
was of a comparable magnitude to that found in subjects 
with obstructive CAD.
To date, few studies have investigated and compared 
the profiles of metabolic abnormalities and obesity or 
the differences in IR between CAD and CSX. Moreover, 
the usefulness of OGTT based IR or insulin-sensitivity 
indices, or glycated hemoglobin (HbA1C) for differenti-
ating between CSX and CAD, who did not have known 
diabetes mellitus (DM), remains unexplored. The aims of 
the present study were to compare IR, including OGTT-
derived indices, and profiles of metabolic abnormalities 
and obesity in CSX and CAD.
Methods
Study population
From April 2011 to May 2013, a total of 5299 cardiac 
catheterization procedures, including CAG, percuta-
neous coronary or peripheral vascular interventions, 
electrophysiological studies, catheter radiofrequency 
ablations, and pacemaker implantations, were performed 
at our catheterization laboratories. Among them, 3250 
catheterizations were for CAG or CAG plus percutane-
ous coronary intervention for angina pectoris or acute 
coronary syndromes. Among the patients undergoing 
these procedures, 240 angina patients without known 
DM, who were admitted for CAG, agreed to receive 
OGTT and HbA1C tests 2 weeks after hospital discharge 
(Fig.  1). Three of them were excluded in this analy-
sis because of severe left ventricular dysfunction with 
ejection fraction lower than 35% and decompensated 
heart failure. Subjects with significant coronary steno-
sis (SYNTAX score  >0) [18] or past histories of surgi-
cal or percutaneous coronary revascularization before 
the index admission were assigned to the CAD group 
(N = 145). Subjects with non-invasive tests for myocar-
dial ischemia but with normal or near normal coronary 
angiograms (SYNTAX score =  0) [18] were assigned to 
the CSX (N =  92) (Fig.  1). We retrospectively reviewed 
all patients’ angiographic images, catheterization reports, 
and medical chart records. The study protocol was 
approved by the Human Research Review Committee of 
Taichung Veterans General Hospital (Taichung, Taiwan).
Definition of metabolic health and obesity
The definition of obesity was BMI equal to or greater than 
25 kg/m2 [19]. The evaluation of the number of metabolic 
abnormalities, including hypertension, high glucose, 
triglycerides, and low HDL-C, was done in accordance 
with the ATP III criteria [20]. Participants who met ≥2 
of the following four criteria were considered metaboli-
cally unhealthy: high triglycerides (≥150  mg/dl) or tak-
ing lipid-lowering drugs, elevated systolic blood pressure 
(≥130 mmHg) or diastolic blood pressure (≥85 mmHg) 
or taking anti-hypertensive drugs, high fasting glucose 
(≥100  mg/dl) or taking medications for diabetes (insu-
lin or oral anti-diabetic), and low HDL-C (<40  mg/dl 
for men and  <50  mg/dl for women). The waist circum-
ference criterion was not used because of its collinearity 
with BMI. We used this definition alongside data on BMI 
to create four phenotypes: metabolically healthy non-
obesity (MHNO); metabolically healthy obesity (MHO); 
metabolically unhealthy non-obesity (MUHNO); meta-
bolically unhealthy obesity (MUHO) [13, 21].
Oral glucose tolerance test, glycated hemoglobin 
(HbA1C), insulin resistance indices, circulating adipokines, 
and high‑sensitivity C‑reactive protein (hs‑CRP)
The study subjects underwent blood tests and OGTT 
after an overnight fast to investigate abnormal glucose 
regulation (AGR). After a fasting blood sample was col-
lected, glucose load of 75  g was ingested over 5  min. 
Blood samples were collected at fasting, and 30 and 
120  min after the test load. Blood glucose and insulin 
concentrations were measured in each sample. Serum 
insulin was determined by a commercially available assay 
kit (Roche Diagnostic, Mannheim, Germany). The detect-
able range was 0.2–1000  µIU/ml. The intra- and inter-
assay coefficients of variation for insulin were 1.9–2.0% 
and 2.5–2.8%, respectively. Fasting insulin resistance was 
estimated using the homeostasis model assessment of 
IR (HOMA-IR), defined as fasting glucose mg/dl × fast-
ing insulin μU/ml/405 [22, 23]. OGTT-derived Matsuda 
insulin-sensitivity index was defined as 10,000/sqrt [fast-
ing glucose (mM) × fasting insulin (μU/ml) × mean glu-
cose during OGTT (mM) × mean insulin during OGTT 
(μU/ml)] [24]. HbA1c was measured by boronate affinity 
high-performance liquid chromatography (CLC385TM, 
Primus Corporation, Kansas City, MO, USA). The intra- 
and inter-assay coefficients of variation for HbA1c [range 
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22  mmol (4.2%)–191  mmol/mol (19.6%)] were  <0.9 
and <2.9%, respectively. The diagnostic criteria for AGR 
were based on the American Diabetes Association defi-
nition [25]. Serum adiponectin, leptin and high-sensi-
tivity C-reactive protein (hs-CRP) were determined by 
enzyme-linked immunosorbent assays (R&D Systems, 
Inc., Minneapolis, MN, USA). The intra- and inter-assay 
coefficients of variation for adiponectin were 3.53 and 
6.50%, respectively, with a minimum detectable concen-
tration of 0.079–0.891 ng/ml. The intra- and inter-assay 
coefficients of variation for leptin were 3.17 and 4.37%, 
respectively, with a minimum detectable concentration 
of  <7.8  pg/ml. The intra- and inter-assay coefficients of 
variance for hs-CRP were 3.8–8.3% and 6.0–7.0%, respec-
tively, with a mean minimum detectable concentration of 
0.010 ng/ml.
Statistical analysis
Continuous variables were expressed as median (inter-
quartile range, 25th percentile to 75th percentile) for 
non-normally distributed data or as mean  ±  standard 
deviation for normally distributed data. Categorical 
data were expressed as percentages. Differences in non-
normally distributed continuous variables between CAD 
and CSX were compared by Mann–Whitney U test while 
normally distributed data were analyzed by Student’s t 
test. Categorical variables were compared using the Chi 
square test or Fisher’s exact test as indicated. Binary 
logistic regression analyses were used to test significant 
variables associated with the diagnosis of CAD in com-
parison with CSX. Receiver operating characteristic 
curve (ROC) analysis was performed using OGTT 2  h 
insulin for differentiating the diagnosis of CAD vs. CSX. 
The SPSS (version, 12.1) statistical software package 
(SPSS, Inc., Chicago, IL, USA) was used for all calcula-
tions. A two-tailed p value of less than 0.05 was consid-
ered statistically significant.
Results
Baseline demographic data, inflammatory marker, 
and lipid profiles in subjects with CAD vs. CSX
The subjects in the CAD group were older and the pro-
portions of male gender and hypertension were higher 
than those in the CSX group (Table 1). The CAD group 
had lower total cholesterol and low-density lipoprotein 
cholesterol (LDL-C), but more subjects were taking lipid-
lowering medication before or after the index admission 
(p  <  0.001) than those in the CSX group. Hs-CRP and 
the circulating adipokines were similar between the two 
groups (Table 1).
Revised diagnosis for abnormal glucose regulation 
after OGTT and HbA1C tests for subjects with CAD vs. CSX 
(status without known DM)
Combining OGTT and HbA1C tests, the subjects in the 
CAD group had more newly diagnosed DM (31.0 vs. 
9.8%) but less newly diagnosed pre-DM (60.0 vs. 72.8%, 
p < 0.001) than those in the CSX group (Table 2).
Insulin resistance and sensitivity indices in subjects 
with CAD vs. CSX (status without known DM)
The fasting indices, including fasting glucose, insulin 
or HOMA-IR, were similar between the CSX and CAD 
groups. OGTT 30  min glucose and insulin levels were 
also similar between the two groups. However, subjects 
in the CAD group had higher values of HbA1C, OGTT 
2  h glucose, and 2  h insulin and a trend (p  =  0.054) 
toward lower OGTT-derived Matsuda insulin-sensitivity 
index than those in the CSX group (Table 3).
Obesity and metabolic health status in subjects with CAD 
vs. CSX (status without known DM)
Both the CAD and CSX groups had a high prevalence of 
obesity (58.6 vs. 50%, p = 0.228), but the CAD group had 
Fig. 1 Flow chart of the study enrollment protocol. CAD: coronary 
artery disease; CAG: coronary angiogram; CSX: cardiac syndrome 
XDM: diabetes mellitus; HbA1C: glycated hemoglobin; LV: left ven‑
tricle; OGTT: oral glucose tolerance test; PCI: percutaneous coronary 
intervention
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more metabolically unhealthy subjects (81.4 vs. 51.1%, 
p  <  0.0001) than the CSX group. Moreover, the CAD 
group had a greater proportion of subjects with meta-
bolically unhealthy obesity (52.4 vs. 31.5%), and fewer 
subjects with metabolically healthy obesity (6.2 vs. 18.5%, 
p =  0.001) in comparison with those in the CSX group 
(Table 4).
Binary logistic regression analysis of independent 
metabolic or IR variables for differentiating the diagnosis 
of CAD vs. CSX (status without known DM)
In the binary regression analysis, OGTT 2 h insulin con-
centration was significantly different between the CAD 
and CSX groups while the Matsuda index, HbA1C, fasting 
glucose, fasting insulin, OGTT 2  h glucose (p =  0.139) 
or HOMA-IR (p = 0.554) were not significantly different 
(Table  5). Being metabolically unhealthy was also a sig-
nificant parameter for differentiating between CAD and 
CSX (Table 5).
Receiver operating characteristic curve analysis using 
OGTT 2 h insulin for differentiating CAD vs. CSX (status 
without known DM)
ROC curve analysis was performed using OGTT 2  h 
insulin for differentiating the diagnosis of CAD vs. CSX, 
the area under the curve was 0.618 (95% confidence 
interval 0.546–0.690, p = 0.002). Using OGTT 2 h insulin 
64.9 µIU/ml as the cut-off value, the sensitivity was 57% 
for the diagnosis of CAD, and the specificity was 69% 
for the diagnosis of CSX. Adopting OGTT 2 h insulin of 
145.6 µIU/ml as the cut-off value, the sensitivity was 15% 
for the diagnosis of CAD, and the specificity was 95% for 
the diagnosis of CSX.
Discussion
The main finding of our study was that higher OGTT 2 h 
insulin level and being metabolically unhealthy were use-
ful indices for differentiating between CAD and CSX in 
subjects undergoing CAG for angina pectoris but with-
out known DM history. However, the Matsuda index, 
HbA1C, fasting glucose, insulin, OGTT 2  h glucose and 
Table 1 Baseline demographic data of  subjects with  car-
diac syndrome X vs. coronary artery disease (status with-
out known diabetes mellitus)
Non-normally distributed data are expressed as median (interquartile range, 25th 
percentile to 75th percentile)
CAD coronary artery disease, CSX cardiac syndrome X, HDL-C high-density 
lipoprotein cholesterol, Hs-CRP high sensitivity C-reactive protein, LDL-C low-






Age (years) 59 ± 11 62 ± 13 0.015
Gender (M/F) 62/30 132/13 <0.001
Hypertension (N) (%) 71 (77%) 134 (92%) 0.002
Systolic blood pressure 
(mmHg)
125 (114, 135) 128 (117, 141) 0.049
Body mass index (kg/m2) 25.0 (23.9, 27.3) 25.9 (23.7, 28.2) 0.174
Current smoking (N) (%) 51 (55%) 86 (60%) 0.563
Total cholesterol (mg/dl) 185 (165, 209) 165 (143, 193) <0.001
LDL‑C (mg/dl) 107 (91, 122) 90 (74, 112) <0.001
HDL‑C (mg/dl) 48 (43, 58) 43 (38, 51) <0.001
Triglycerides (mg/dl) 122 (88, 173) 118 (88, 164) 0.960
Adiponectin (μg/ml) 3.7 (1.5, 6.0) 3.6 (1.5, 5.8) 0.583
Leptin (ng/ml) 4.2 (2.3, 8.5) 4.5 (2.8, 8.3) 0.627
Hs‑CRP (mg/dl) 0.09 (0.02, 0.25) 0.12 (0.05, 0.26) 0.104
Medication before index admission
Use of statin (N) (%) 13 (14%) 56 (39%) <0.001
Use of fibrates (N) (%) 2 (2%) 1 (0.7%) 0.689
Use of anti‑hypertensive 
medication (N) (%)
71 (77%) 134 (92%) 0.002
Medication post index  
admission
Use of statin (N) (%) 22 (24%) 100 (69%) <0.001
Table 2 Revised diagnosis for  abnormal glucose regulation after  OGTT and  HbA1C tests for  subjects with  cardiac syn-
drome X vs. coronary artery disease (status without known diabetes mellitus)








(normal fasting glucose, OGTT & HbA1C)
16 (17.4%) 13 (9.0%) <0.001
Newly diagnosed diabetes mellitus (N)(%) (fasting glucose, OGTT or HbA1C) 9 (9.8%) 45 (31.0%)
Pre‑diabetes (N) (%) 67 (72.8%) 87 (60.0%)
IFG (N) 8 9
IGT (N) 23 34
IFG + IGT (N) 11 16
HbA1C (5.7–6.4%) (N) 55 83
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HOMA-IR were not significant variables for distinguish-
ing between CAD and CSX.
Our previous studies showed a high prevalence of 
newly diagnosed AGR in subjects undergoing CAG 
but without known DM [26, 27]. In this study, we fur-
ther investigated and compared the prevalence of newly 
diagnosed DM, pre-DM, including impaired fasting glu-
cose, impaired glucose tolerance or both, and abnormal 
HbA1C in CAD vs. CSX. Combining OGTT and HbA1C 
tests revealed a very high prevalence of newly diagnosed 
AGR in both the CSX and CAD groups. A novel finding 
in this study was that there was a greater proportion of 
newly diagnosed DM in the CAD group, but a higher 
prevalence of newly diagnosed pre-DM was found in the 
CSX group (Table  2). This implies that IR is one of the 
important mechanisms underlying the pathogenesis of 
both CAD and CSX and the different degrees of IR might 
contribute to the phenotype of DM vs. pre-DM as well as 
obstructive vs. non-obstructive coronary diseases.
Whether there is a difference in the prevalence of obe-
sity or metabolic abnormalities between CSX and CAD 
has rarely been investigated. Moreover, there are incon-
sistent data on whether metabolically healthy obesity 
increases DM or cardiovascular risk to the same extent 
as metabolically unhealthy obesity does [13, 21]. In this 
study, we found a high prevalence of obesity in both CAD 
and CSX. CAD subjects had a higher prevalence of meta-
bolic unhealthiness as well as metabolically unhealthy 
obesity in comparison with the CSX subjects (Table  4). 
Being metabolically unhealthy was a significant param-
eter for differentiating CAD vs. CSX (Table 5). The differ-
ent prevalence rates of metabolic dysfunction, along with 
the difference in IR imply that the different degrees of 
metabolic derangements may underlie the development 
of macro- or micro-vascular disease in coronary trees.
A novel finding of this study showed that OGTT 2  h 
insulin was a significant parameter in the differential 
diagnosis between CAD vs. CSX while fasting glucose, 
insulin, HOMA-IR and HbA1C were not. One study 
reported that HOMA-IR but not the Matsuda index was 
a predictor for CAD in subjects with angina but without 
DM undergoing CAG [28]. Another study reported that 
the CAD group had a higher OGTT post-challenge insu-
lin level as compared with that of the non-CAD group 
[29]. Several population-based studies have applied fast-
ing insulin level or HOMA-IR as a marker of insulin 
resistance and have shown significant associations with 
cardiovascular events in non-diabetic individuals, inde-
pendent of other risk factors [30, 31]. One small-scale 
Table 3 Insulin-resistance indices in subjects with cardiac syndrome X vs. coronary artery disease (status without known 
diabetes mellitus)
Non-normally distributed data are expressed as median (interquartile range, 25th percentile to 75th percentile)






HbA1C (%) 5.8 (5.6, 6.1) 6.0 (5.7, 6.4) 0.002
Fasting glucose (mg/dl) 93 (87, 100) 94 (89, 102) 0.115
OGTT 30 min glucose (mg/dl) 163 (146, 184) 165 (149, 188) 0.204
OGTT 2 h glucose (mg/dl) 127 (106, 155) 143 (114, 186) 0.004
Fasting insulin (µIU/ml) 8.3 (5.1, 13.8) 9.4 (6.0, 15.7) 0.317
OGTT 30 min insulin (µIU/ml) 65.0 (38.9, 99.9) 61.4 (39.1, 94.7) 0.817
OGTT 2 h insulin (µIU/ml) 47.3 (34.6, 75.9) 68.3 (40.1, 116.7) 0.002
HOMA‑IR (mg/dl × µIU/ml) 2.0 (1.2, 3.3) 2.2 (1.3, 3.8) 0.231
OGTT derived insulin‑sensitivity index, Matsuda (mM × µIU/ml)−1 87.1 (53.7, 143.0) 68.9 (46.8, 117.7) 0.054
Table 4 Metabolic health and  obesity status in  subjects 
with  cardiac syndrome X vs. coronary artery disease (sta-
tus without known diabetes mellitus)
Metabolically unhealthy: who met ≥2 of the following four criteria: high 
triglycerides (≥150 mg/dl) or taking lipid-lowering drugs, elevated systolic 
blood pressure (≥130 mmHg) or diastolic blood pressure (≥85 mmHg) or 
taking anti-hypertensive drugs, high fasting glucose (≥100 mg/dl) or taking 
medications for diabetes (insulin or oral anti-diabetic), and low high-density 
lipoprotein cholesterol (<40 mg/dl for men and <50 mg/dl for women)
Obesity body mass index equal to or greater than 25 kg/m2
MHNO metabolically healthy non-obesity, MHO metabolically healthy obesity, 








MHNO 28 (30.4%) 18 (12.4%)
MHO 17 (18.5%) 9 (6.2%)
MUHNO 18 (19.6%) 42 (29%)
MUHO 29 (31.5%) 76 (52.4%)
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study reported that CSX and CAD subjects had a higher 
OGTT 2  h insulin than that of the controls, and CAD 
and CSX subjects had similar insulin responses in OGTT 
[17]. Our study revealed that CAD subjects had higher 
OGTT 2 h insulin levels, but the fasting IR indices were 
similar to those seen in CSX subjects. In the IR status, 
compensatory hyper-insulinemia might work only via the 
mitogenic pathway and promote vascular smooth muscle 
growth and migration [32], which would impair vaso-
relaxation and contribute to the pathogenesis of CSX and 
CAD. Our study result implied that the degree and the 
difference in IR might be implicated in the obstructive vs. 
non-obstructive, as well in the micro-vascular vs. macro-
vascular coronary disease. In OGTT test, 2  h insulin 
reflects the response of beta cells and peripheral tissues 
after a glucose challenge and is a better and more sensi-
tive reflection of post-stimulated IR than fasting glucose 
or insulin [33]. Our study showed that the difference in 
IR between CAD and CSX was subtle and required a 
more refined test to determine.
Some studies used a stricter definition for CSX, exclud-
ing subjects with DM [2]. In this study, we used OGTT 
and A1C tests for screening for AGR in subjects with 
angina pectoris undergoing CAG but without known or 
overt DM. If we excluded newly diagnosed DM cases and 
reanalyzed the data, OGTT 2 h insulin remained a useful 
and significant IR parameter for differentiating between 
CAD and CSX.
There were several limitations in this study. This was 
a cross-sectional study that was conducted in a single 
catheterization laboratory within a specific time frame 
so selection bias could not be avoided. Because the 
study subjects needed to agree with OGTT tests post 
discharge and should not have known DM, only 237 
Table 5 Binary logistic regression analysis of  independent metabolic variables for  diagnostic differentiation 
between coronary artery disease and cardiac syndrome X (status without known diabetes mellitus)
Metabolically unhealthy: who met ≥2 of the following four criteria: high triglycerides (≥150 mg/dl) or took lipid-lowering drugs, elevated systolic blood pressure 
(≥130 mmHg) or diastolic blood pressure (≥85 mmHg) or took anti-hypertensive drugs, high fasting glucose (≥100 mg/dl) or took medications for diabetes (insulin or 
oral anti-diabetic), and low high-density lipoprotein cholesterol (<40 mg/dl for men and <50 mg/dl for women)
CI confidence interval, HOMA-IR homeostasis model assessment (HOMA) index of insulin-resistance = (fasting glucose mg/dl x fasting insulin μU/ml)/405, OGTT oral 
glucose tolerance test, OR odds ratio, pre-index statin use use of HMG-CoA reductase inhibitor before index admission
a Dependent variable: coronary artery disease vs. cardiac syndrome X
b Independent variables: demographic data, body mass index, metabolically unhealthy, statin use, and HOMA-IR
c Independent variables: demographic data, body mass index, metabolically unhealthy, statin use, and OGTT 2 h glucose
d Independent variables: demographic data, body mass index, metabolically unhealthy, statin use, and OGTT 2 h insulin
Factors p value OR 95% CI
Lower limit Upper limit
Mode 1. Metabolic health and HOMA-IR indexa, b
Age (years) 0.010 1.036 1.009 1.064
Gender (male vs. female) <0.001 4.867 2.184 10.849
Body mass index (kg/m2) 0.449 1.036 0.946 1.135
Metabolically unhealthy (unhealthy vs. healthy) 0.004 2.680 1.380 5.204
HOMA‑IR (mg/dl × µIU/ml) 0.554 1.022 0.950 1.099
Pre‑admission statin use (with vs. without) 0.005 2.901 1.388 6.061
Mode 2. Metabolic health and OGTT 2 h glucosea, c
Age (years) 0.045 1.029 1.001 1.058
Gender (male vs. female) <0.001 5.169 2.290 11.669
Body mass index (kg/m2) 0.336 1.043 0.958 1.135
Metabolically unhealthy (unhealthy vs. healthy) 0.014 2.368 1.194 4.696
OGTT 2 h glucose (mg/dl) 0.139 1.006 0.998 1.013
Pre‑admission statin use (with vs. without) 0.004 3.037 1.436 6.423
Mode 3. Metabolic health and OGTT 2 h insulina, d
Age (years) 0.012 1.036 1.008 1.065
Gender (male vs. female) <0.001 6.544 2.763 15.502
Body mass index (kg/m2) 0.798 1.012 0.924 1.109
Metabolically unhealthy (unhealthy vs. healthy) 0.013 2.364 1.200 4.658
OGTT 2 h insulin (µIU/ml) 0.004 1.010 1.003 1.017
Pre‑admission statin use (with vs. without) 0.005 2.939 1.381 2.657
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patients were enrolled. The smaller sample size would 
limit its impact and interpretation. We did not meas-
ure c-peptide and thus the difference in circulating 
insulin concentration could not be attributed to the dif-
ference in beta cell production in response to glucose 
load or the difference in insulin clearance from circula-
tion. Whether the difference in OGTT-based IR had an 
impact on cardiovascular outcome in the CAD or CSX 
subjects was not investigated in this study. The mech-
anisms why difference in IR appeared to reflect the 
clinical phenotypes of coronary disease, obstructive vs. 
non-obstructive, warrant further in vitro study. Moreo-
ver, we did not include some newly investigated mark-
ers, such as carotid intima media thickness, neutrophil 
and lymphocyte (N/L) ratios, or erectile dysfunction 
scores as comparing variables in this study [34, 35].
In conclusion, OGTT 2  h insulin level and meta-
bolic unhealthiness were found to be useful diagnostic 
parameters for differentiating between CAD and CSX 
in subjects with angina pectoris undergoing CAG but 
without known DM, whereas fasting IR or HbA1C indi-
ces were not. There were greater prevalence rates of 
metabolically unhealthy obesity and newly diagnosed 
DM among subjects with CAD compared with those of 
subjects in the CSX group.
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